Insulet Corporation (NASDAQ:PODD) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Insulet Corporation has received a consensus rating of "Moderate Buy" from analysts, with 18 buy ratings and 3 hold ratings among the 21 firms covering the stock.
• The average 12-month target price for Insulet shares is $348.05, with recent price targets raised by various brokerage firms, including JPMorgan's adjustment to $415.00.
• Insider selling has occurred recently, with two senior vice presidents reducing their holdings by approximately 16.58% and 17.00% through stock transactions at prices around $347-$348.

Shares of Insulet Corporation (NASDAQ:PODD - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-one ratings firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $348.0526.

Several brokerages recently issued reports on PODD. Canaccord Genuity Group raised their target price on shares of Insulet from $353.00 to $399.00 and gave the stock a "buy" rating in a report on Monday, September 29th. Barclays boosted their price target on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. JPMorgan Chase & Co. increased their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. Wells Fargo & Company boosted their price target on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Finally, Royal Bank Of Canada lifted their price objective on Insulet from $350.00 to $365.00 and gave the company an "outperform" rating in a research report on Friday, October 10th.

Insiders Place Their Bets

In related news, SVP Prem Singh sold 687 shares of the company's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Institutional Investors Weigh In On Insulet

A number of institutional investors have recently added to or reduced their stakes in PODD. Zions Bancorporation National Association UT bought a new position in shares of Insulet during the first quarter worth $26,000. Larson Financial Group LLC lifted its stake in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 69 shares in the last quarter. SouthState Corp increased its holdings in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 76 shares during the last quarter. Finally, Kozak & Associates Inc. bought a new stake in shares of Insulet in the second quarter worth about $32,000.

Insulet Trading Up 1.2%

NASDAQ PODD opened at $318.30 on Wednesday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market cap of $22.41 billion, a P/E ratio of 96.75, a P/E/G ratio of 2.63 and a beta of 1.40. Insulet has a 12 month low of $226.50 and a 12 month high of $353.50. The stock's fifty day moving average price is $325.03 and its 200-day moving average price is $301.15.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period in the prior year, the company posted $0.55 earnings per share. The company's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts forecast that Insulet will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.